Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.63
CORT's Cash to Debt is ranked lower than
73% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. CORT: 1.63 )
Ranked among companies with meaningful Cash to Debt only.
CORT' s Cash to Debt Range Over the Past 10 Years
Min: 0.72  Med: 1144.31 Max: No Debt
Current: 1.63
Equity to Asset 0.38
CORT's Equity to Asset is ranked lower than
78% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CORT: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
CORT' s Equity to Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.58 Max: 0.89
Current: 0.38
-0.1
0.89
Interest Coverage 0.42
CORT's Interest Coverage is ranked lower than
98% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CORT: 0.42 )
Ranked among companies with meaningful Interest Coverage only.
CORT' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.00 Max: 9999.99
Current: 0.42
N/A
9999.99
F-Score: 6
Z-Score: 4.72
M-Score: -2.87
WACC vs ROIC
13.53%
21.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 2.10
CORT's Operating margin (%) is ranked higher than
72% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. CORT: 2.10 )
Ranked among companies with meaningful Operating margin (%) only.
CORT' s Operating margin (%) Range Over the Past 10 Years
Min: -69827.59  Med: -1818.64 Max: -6.85
Current: 2.1
-69827.59
-6.85
Net-margin (%) -2.84
CORT's Net-margin (%) is ranked higher than
68% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. CORT: -2.84 )
Ranked among companies with meaningful Net-margin (%) only.
CORT' s Net-margin (%) Range Over the Past 10 Years
Min: -69537.93  Med: -1775.79 Max: -12.74
Current: -2.84
-69537.93
-12.74
ROE (%) -10.76
CORT's ROE (%) is ranked higher than
67% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. CORT: -10.76 )
Ranked among companies with meaningful ROE (%) only.
CORT' s ROE (%) Range Over the Past 10 Years
Min: -356.04  Med: -113.30 Max: -78.79
Current: -10.76
-356.04
-78.79
ROA (%) -3.20
CORT's ROA (%) is ranked higher than
73% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. CORT: -3.20 )
Ranked among companies with meaningful ROA (%) only.
CORT' s ROA (%) Range Over the Past 10 Years
Min: -124.18  Med: -87.40 Max: -14.8
Current: -3.2
-124.18
-14.8
ROC (Joel Greenblatt) (%) 47.09
CORT's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CORT: 47.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CORT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -391957.14  Med: -49033.54 Max: -142.89
Current: 47.09
-391957.14
-142.89
Revenue Growth (3Y)(%) 135.50
CORT's Revenue Growth (3Y)(%) is ranked higher than
96% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CORT: 135.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CORT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 230.2
Current: 135.5
0
230.2
EBITDA Growth (3Y)(%) -57.00
CORT's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CORT: -57.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CORT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -16.85 Max: 4
Current: -57
0
4
EPS Growth (3Y)(%) -47.30
CORT's EPS Growth (3Y)(%) is ranked lower than
88% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CORT: -47.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CORT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.3  Med: -11.20 Max: 6.7
Current: -47.3
-47.3
6.7
» CORT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CORT Guru Trades in Q2 2015

First Eagle Investment 200,000 sh (New)
Jim Simons 501,614 sh (+805.44%)
» More
Q3 2015

CORT Guru Trades in Q3 2015

Paul Tudor Jones 21,279 sh (New)
Joel Greenblatt 17,221 sh (New)
David Swensen 22,334 sh (New)
First Eagle Investment 300,000 sh (+50.00%)
Jim Simons 452,200 sh (-9.85%)
» More
Q4 2015

CORT Guru Trades in Q4 2015

Paul Tudor Jones 27,099 sh (+27.35%)
Jim Simons 460,400 sh (+1.81%)
Joel Greenblatt 17,347 sh (+0.73%)
First Eagle Investment 300,000 sh (unchged)
David Swensen Sold Out
» More
Q1 2016

CORT Guru Trades in Q1 2016

First Eagle Investment 395,670 sh (+31.89%)
Paul Tudor Jones 28,799 sh (+6.27%)
Joel Greenblatt Sold Out
Jim Simons 191,400 sh (-58.43%)
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:IPHYF, NAS:ATRA, OTCPK:SNBIF, OTCPK:GNFTF, NAS:NTLA, NAS:INO, NAS:CERS, NAS:ANIP, OTCPK:BIESF, NAS:INSM, NAS:CASC, NAS:ZIOP, NAS:DVAX, NAS:PACB, NAS:BPMC, NAS:PDLI, OTCPK:PHMMF, NAS:MACK, NAS:EPZM, NAS:GBT » details
Traded in other countries:HTD.Germany,
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders associated with thesteroid hormone cortisol.

Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. The Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.

Ratios

vs
industry
vs
history
P/B 32.01
CORT's P/B is ranked lower than
96% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. CORT: 32.01 )
Ranked among companies with meaningful P/B only.
CORT' s P/B Range Over the Past 10 Years
Min: 1.82  Med: 9.81 Max: 86.18
Current: 32.01
1.82
86.18
P/S 11.35
CORT's P/S is ranked higher than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. CORT: 11.35 )
Ranked among companies with meaningful P/S only.
CORT' s P/S Range Over the Past 10 Years
Min: 7.18  Med: 182.73 Max: 1990
Current: 11.35
7.18
1990
PFCF 196.34
CORT's PFCF is ranked lower than
92% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. CORT: 196.34 )
Ranked among companies with meaningful PFCF only.
CORT' s PFCF Range Over the Past 10 Years
Min: 135.67  Med: 171.67 Max: 200.33
Current: 196.34
135.67
200.33
POCF 77.50
CORT's POCF is ranked lower than
82% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. CORT: 77.50 )
Ranked among companies with meaningful POCF only.
CORT' s POCF Range Over the Past 10 Years
Min: 53.55  Med: 74.54 Max: 182.41
Current: 77.5
53.55
182.41
EV-to-EBIT 535.18
CORT's EV-to-EBIT is ranked lower than
99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. CORT: 535.18 )
Ranked among companies with meaningful EV-to-EBIT only.
CORT' s EV-to-EBIT Range Over the Past 10 Years
Min: -160.5  Med: -6.00 Max: 545.7
Current: 535.18
-160.5
545.7
EV-to-EBITDA 477.65
CORT's EV-to-EBITDA is ranked lower than
99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. CORT: 477.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
CORT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -168  Med: -6.00 Max: 487
Current: 477.65
-168
487
Current Ratio 2.10
CORT's Current Ratio is ranked lower than
75% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CORT: 2.10 )
Ranked among companies with meaningful Current Ratio only.
CORT' s Current Ratio Range Over the Past 10 Years
Min: 2.1  Med: 7.46 Max: 37.77
Current: 2.1
2.1
37.77
Quick Ratio 2.02
CORT's Quick Ratio is ranked lower than
71% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. CORT: 2.02 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s Quick Ratio Range Over the Past 10 Years
Min: 2.02  Med: 7.46 Max: 37.77
Current: 2.02
2.02
37.77
Days Inventory 397.41
CORT's Days Inventory is ranked lower than
92% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. CORT: 397.41 )
Ranked among companies with meaningful Days Inventory only.
CORT' s Days Inventory Range Over the Past 10 Years
Min: 387.39  Med: 1093.61 Max: 2487.36
Current: 397.41
387.39
2487.36
Days Sales Outstanding 43.82
CORT's Days Sales Outstanding is ranked higher than
66% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. CORT: 43.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.16  Med: 48.08 Max: 61.48
Current: 43.82
45.16
61.48
Days Payable 519.79
CORT's Days Payable is ranked higher than
95% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. CORT: 519.79 )
Ranked among companies with meaningful Days Payable only.
CORT' s Days Payable Range Over the Past 10 Years
Min: 355.35  Med: 3428.94 Max: 15257.8
Current: 519.79
355.35
15257.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 83.29
CORT's Price/Net Cash is ranked lower than
96% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. CORT: 83.29 )
Ranked among companies with meaningful Price/Net Cash only.
CORT' s Price/Net Cash Range Over the Past 10 Years
Min: 2.5  Med: 6.21 Max: 376
Current: 83.29
2.5
376
Price/Net Current Asset Value 36.44
CORT's Price/Net Current Asset Value is ranked lower than
92% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. CORT: 36.44 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CORT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.43  Med: 6.12 Max: 93.33
Current: 36.44
2.43
93.33
Price/Tangible Book 31.68
CORT's Price/Tangible Book is ranked lower than
94% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CORT: 31.68 )
Ranked among companies with meaningful Price/Tangible Book only.
CORT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.31  Med: 6.13 Max: 82.35
Current: 31.68
2.31
82.35
Price/Median PS Value 0.06
CORT's Price/Median PS Value is ranked higher than
99% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CORT: 0.06 )
Ranked among companies with meaningful Price/Median PS Value only.
CORT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.51 Max: 7.17
Current: 0.06
0.05
7.17
Earnings Yield (Greenblatt) (%) 0.20
CORT's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. CORT: 0.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CORT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 0.20 Max: 0.3
Current: 0.2
0.2
0.3

More Statistics

Revenue (TTM) (Mil) $56.25
EPS (TTM) $ -0.07
Beta1.62
Short Percentage of Float8.59%
52-Week Range $3.22 - 6.33
Shares Outstanding (Mil)109.80
» More Articles for CORT

Headlines

Articles On GuruFocus.com
David Swensen Bets on Antero Resources Mar 10 2016 
Two Stocks for the Value Investor and GAARP Enthusiast Jun 07 2014 
Corcept Therapeutics Inc. Reports Operating Results (10-K/A) Aug 19 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 16 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Nov 12 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 11 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) May 13 2009 

More From Other Websites
Everybody's Doing It: 5 Stocks Under $10 That I Like Jul 14 2016
Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining... Jun 29 2016
Corcept Therapeutics Appoints Renée D. Galá to Board of Directors Jun 28 2016
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 28 2016
Corcept Therapeutics Appoints Renee D. Gala to Board of Directors Jun 28 2016
Explosive Stocks Under $10 Jun 28 2016
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : June... Jun 27 2016
Corcept (CORT) Reports Early Breast Cancer Data on Korlym Jun 03 2016
Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program Jun 02 2016
Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program Jun 02 2016
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 19 2016
ETF’s with exposure to Corcept Therapeutics, Inc. : May 12, 2016 May 12 2016
CORCEPT THERAPEUTICS INC Financials May 11 2016
Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q1, 2016 By the Numbers May 10 2016
Corcept (CORT) Posts In-Line Q1 Earnings, Korlym in Focus May 04 2016
CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 04 2016
Edited Transcript of CORT earnings conference call or presentation 3-May-16 9:00pm GMT May 03 2016
Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update May 03 2016
Corcept beats 1Q profit forecasts May 03 2016
Corcept beats 1Q profit forecasts May 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)